Companies Dominating the Interchangeable Biosimilars Landscape
- Biocon Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Mylan N.V.
- Amgen Inc.
- Coherus BioSciences, Inc.
- Pfizer Inc.
- Sandoz International GmbH
- Merck & Co.
- Boehringer Ingelheim group
- Samsung Bioepis Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2024, the industry size of interchangeable biosimilars is evaluated at USD 35.46 Billion.
The interchangeable biosimilars market size was valued at USD 30.03 Billion in 2023 and is anticipated to exceed USD 324.74 Billion by the end of 2036, registering over 20.1% CAGR during the forecast period i.e., between 2024-2036. Increasing incidences of chronic diseases and the growing availability of over-the-counter drugs along with the rising focus on health and fitness are the major factors driving the market growth.
Asia Pacific is poised to account for majority industry share by 2036, on the back of advancement in the healthcare infrastructure, along with growing number of researchers involved in R&D activities in the region.
Biocon Limited, Mylan N.V., Amgen Inc., Coherus BioSciences, Inc., Pfizer Inc., Sandoz International GmbH, Merck & Co., Boehringer Ingelheim group, Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd.
